Meta-Analysis Suggests Ketofol Is Safer Than Propofol Alone

Pooling of data from several trials suggests fewer respiratory and cardiovascular adverse events with ketofol.

Investigators conducted a meta-analysis of randomized trials comparing ketofol (a 1:1 or 1:4 combination of ketamine and propofol) to propofol alone for procedural sedation in adults to compare adverse events associated with the two approaches.

Eighteen studies involving roughly 2100 adult patients were included in the pooled analysis. With ketofol, compared to propofol, the risk of respiratory suppression requiring an intervention was 0.47 in the 14 trials that measured this outcome, the risk of hypotension was 0.41 in 9 trials, and the risk of bradycardia was 0.47 in 8 trials. Nausea and psychomimetic complications did not differ between the pooled ketofol and propofol groups.

Reviewing Author

Daniel J. Pallin, MD, MPH

Disclosures

Consultant/Advisory BoardPortola Pharmaceuticals, Inc.

Speaker’s BureauPeerView Institute for Medical Education

Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals

Daniel J. Pallin, MD, MPH

Disclosures

Consultant/Advisory BoardPortola Pharmaceuticals, Inc.

Speaker’s BureauPeerView Institute for Medical Education

Meta-Analysis Suggests Ketofol Is Safer Than Propofol Alone

Topics

Reviewing Author